Tejava Ice Tea Recall Issued Due to Glass Fragment Contamination

A nationwide recall of Tejava Premium Iced Tea has been issued after it was discovered that some 12 oz bottles may be contaminated by glass fragments. 

The Tejava ice tea recall was announced by the FDA on December 9, after the company reported the problems.

Although there have been no reports of illness or injury resulting from the contaminated ice tea bottles, the manufacturer indicates that the glass fragments may be harmful if swallowed.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The recall affects Tejava Premium Iced Tea in 12 oz. glass bottles with production lot code dates of 1BT220, 1BT221, 1BT222, 1BT223, 1BT252, 1BT253, 1BT254, 1BT255, 1BT277, 1BT278, 1BT279, 1BT280, and 1BT313. The production codes can be found on the back of the bottle label and on the long panel of the case tray. The cases the bottles were sold in have a UPC of 6-54871-24901-2, the four-packs have a UPC of 6-54871-04901-1, and the single bottles have a UPC of 6-54871-00901-5. The 1 liter bottles of Tejava Premium Iced Tea are not affected by the recall.

The company is asking consumers to return affected bottles of Tejava Premium Iced Tea to the store where it was purchased. The will receive coupons, product replacement or credit. Consumers with questions can call the Tejava Consumer Hotline at (888) 847-8742 or visit the company’s website at www.Tejava.com.


0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Lawsuits over Ozempic and Wegovy vision loss will be consolidated for pretrial proceedings in New Jersey, separate from claims involving gastrointestinal injuries.
Former Becton Dickinson safety officer Dr. Hooman Noorchashm warns that the company’s GalaFLEX mesh is being used off-label in breast reconstruction without FDA approval, as lawsuits investigate whether the manufacturer failed to warn about its potential risks.
A series of case management conferences have been scheduled for hair relaxer litigation throughout 2026, leading up to expected bellwether trials in 2027.